Evonik launches new line of RESOMER® Composites to enhance the performance of bone fixation devices
Evonik, a global leader for advanced biomaterials and application technology solutions for bioresorbable implants, today announced the launch of its first product grade from a new line of RESOMER® Composite polymers.
By integrating the osteoconductive properties of calcium-phosphate based additives into its market-leading RESOMER® portfolio of bioresorbable polymers, Evonik can further support medical device customers worldwide to enhance the performance of orthopaedic applications used to heal or grow bones.
RESOMER® Composites feature precise degradation rate profiles and mechanical properties such as elastic modulus that can be tailored to match the natural bone. Such benefits can help to minimize stress shielding for bone fixation devices such as interference screws, suture anchors and fracture plates to encourage faster patient healing.
A range of standard and customizable product grades with calcium-phosphate material options including Hydroxyapatite (HA), beta-tricalcium phosphate (β-TCP) and Bicalcium phosphate (BCP) will be available under the RESOMER® Composite line. The first composite product to be launched by Evonik is
RESOMER® Composite L 210 S plus 25% HA. Additional standard grades with β-TCP additives are scheduled to be introduced later this year.
RESOMER® Composites are supplied to customers as ready-to-use pellets that are easy to process for a uniform additive distribution. They are also radiolucent to avoid potential interference with X-ray equipment.
Dr. Andreas Karau, Global Head of Biomaterials for Evonik, said: “Our new line of composites combine the osteoconductive benefits of calcium-based phosphates with a 30 year track record of RESOMER® polymers for functionality, biocompatibility, safety and supply security.”
“With elastic modulus properties and tailored degradation profiles that match the natural bone, we look forward to supporting medical device customers to enhance the performance of their bioresorbable implants.”
Medical device companies who are attending the Medtec Europe trade show in Stuttgart, Germany from April 17 to 19 are encouraged to visit Evonik at booth 9C28.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,250 employees, and generated sales of around €4.5 billion in 2017.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.